TX-FLUENCE
24.1.2020 12:02:09 CET | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, announced today it is expanding its presence in the Emsland region of Germany through partnerships with growers and other horticulture specialists operating out of Papenburg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005109/en/
Given Papenburg’s decades-long history of attracting horticulture experts, Fluence’s innovative lighting solutions for horticulture are a natural fit for the region’s tomato, cucumber, leafy greens and herb growers.
Forging connections with Papenburg’s horticultural leaders
Elektro Evers , an engineering firm specializing in greenhouse technology, is Fluence’s exclusive systems integrator in the Papenburg region. Elektro Evers assists customers with installing, integrating and maintaining Fluence’s horticulture lighting systems. The company’s managing director, Norbert Bröring, says Fluence’s partnership is well-suited for the region.
“We are excited to collaborate with Fluence and bring the team’s deep horticulture lighting expertise to Papenburg’s growers,” Bröring said. “As an extension of German lighting innovator OSRAM, we know we’ve found the right partner in Fluence. Together, our advanced solutions will empower customers to cultivate plants under optimal conditions while mitigating energy demands.”
Papenburg’s Gartenbauzentrale —a 100-hectare food cooperative representing 49 family farms—recommends Fluence’s LED solutions to help members produce high-quality, consistent herbs and vegetables throughout the year. The energy savings resulting from LED use also enables Gartenbauzentrale members to apply for EU funding granted for resource conservation.
“Our members seek the most innovative, reliable technology for their farms,” said Marco Lüpken, head of controlling for Gartenbauzentrale. “High and consistent product quality as well as year-round predictable yields are key in our business. Fluence’s precise, high-intensity lighting solutions enable our growers to meet and exceed their growth goals efficiently with better-tasting plants.”
Investing in advanced technology: Greenhouse growers capitalize on LEDs
Friedrich Schulz’s 5.5 hectare farm—which grows herbs year-round in addition to lettuce, peppers and chives—utilizes VYPR 2p fixtures with PhysioSpec Greenhouse spectra across 3,000 square meters of lettuce crop.
“Switching from high pressure sodium lights to Fluence’s LED lights doubled our light intensity, leading to faster, more efficient grow cycles,” Schulz said. “The red lettuce grown under Fluence’s technology produced enhanced coloration within the first week alone. Fluence lighting achieves larger, higher quality yields while also keeping us energy efficient.”
For Reiner Borrmann, leveraging VYPR 2p lights with his basil crop yielded more flavorful, intense-tasting basil after replacing his greenhouse’s HPS lighting fixtures. Borrmann’s farm includes 4 hectares of greenhouse space.
“The energy efficiency allows us to grow more compact crops in less time, and the lights help us observe the plants’ natural colors,” Borrmann said.
Fluence’s general manager of EMEA, Timo Bongartz, said that implementing new LED systems is a decisive factor for a grower’s economic success.
“We are delighted to become an integral part of Papenburg’s cultivation ecosystem to enable growers to succeed in an extremely competitive environment,” Bongartz said. “With our horticulture lighting solutions, they are producing higher- and better-quality yields in less time while garnering significant energy savings. We’re delighted to nurture these partnerships through continued collaboration in the region.”
For more information on Fluence and its solutions for commercial agriculture, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates the most powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is the leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200124005109/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
